Sanofi is a pharmaceutical company engaged in the development, manufacturing, and distribution of a broad range of prescription medicines, consumer healthcare products and generic products worldwide. The company operates through three reportable business segments: Pharmaceuticals, Consumer Healthcare and Vaccines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sanofi’s research and development activities focus on therapy areas such as multiple sclerosis, oncology, neurology, other auto-immune diseases, inflammation, vaccines, and rare blood disorders. The company’s R&D focused on the transformative therapies are fitusiran and efanesoctocog alfa (hemophilia); amlitelimab (Immunology & Inflammation); tolebrutinib (multiple sclerosis); and nirsevimab (prevention of respiratory syncytial virus). Sanofi's dedicated scientists are determined to assist individuals facing immune, autoimmune, and inflammation disorders that have been historically difficult to treat. Through the integration of molecular, clinical, and real-world data, their research and development teams are making significant progress in the field of precision immunology. Sanofi is making substantial investments in the development of the next generation of cancer medicines. With a strong emphasis on clear focus, extensive internal expertise, and strategic collaborations with industry leaders, its scientists are actively engaged in designing innovative and potentially life-transforming medications for cancer patients across the globe. Sanofi is dedicated to creating new medicines that are inspired by patient insights and grounded in exceptional scientific research. Its focus lies in providing support to the millions of individuals who are affected by neurological disorders. By harnessing revolutionary technologies, Sanofi scientists are actively working on the development of targeted therapies that have the potential to modify the course of diseases like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The company has a remarkable history of innovation in the field of hematology, starting from the pioneering development of extended half-life clotting factors for the treatment of hemophilia A and B. Furthermore, they have achieved significant milestones by introducing the first approved treatments for acquired thrombotic thrombocytopenic purpura (aTTP) and cold agglutinin disease. This legacy of innovation underscores their commitment to advancing medical solutions in the field of hematology. Sanofi is deeply committed to making important advancements in the field of rare diseases, with a focus on discovering, developing, and delivering new options for individuals affected by such conditions. The dedicated teams at Sanofi are actively working on the development of innovative medicines for disorders like Fabry, Gaucher, and Pompe diseases. Additionally, they are making significant progress towards finding new treatments for patients with GM2 gangliosidoses (including Tay-Sachs disease, AB variant, and Sandhoff disease) and acid sphingomyelinase deficiency (ASMD) to address unmet medical needs in these areas. Its research and development teams are also actively engaged in the development of vaccine antigens, which are essential molecules that stimulate the immune response in the body to fight against disease-causing pathogens. In addition to their focus on infectious diseases, Sanofi also explores the potential of vaccines in preventing chronic diseases. The company conducts R&D activities for pharmaceuticals at four operational sites located in France: Chilly-Mazarin/Longjumeau, Montpellier, Strasbourg and Vitry-sur-Seine/Alfortville; three sites in the rest of Europe (Germany, Belgium, and the Netherlands); six sites in the United States: Bridgewater, Cambridge, Framingham/Waltham, Great Valley, San Francisco, and San Diego; and three sites located in Asia in China (Beijing, Shanghai and Chengdu). As of February 24 2023, the vaccines research has 11 projects in advanced development stage of its pipeline. The vaccines research and development sites are in Swiftwater, Cambridge and Orlando (the US); Marcy-l’Etoile/Lyon (France); and Toronto (Canada). In FY2022, the company spent EUR6,706 million on R&D, which as a percentage of revenue, stood at 15.6% and grew 17.8% YoY.